PTX

2.44%

4.2¢ prescient therapeutics limited

Ann: PTX-200 AML Trial Progresses to Higher Dose, page-18

First 18 Last

Share
Profile

Follow
dalts66

4,336 Posts.

2023

23/04/21

14:39

Post #: 52682489
Share

Originally posted by davybabyk: ↑

So this is good news, certainly.

I do wish they could be clearer in their Announcements though, and improve communications generally.

From the wording of this Announcement, the three patients successfully dosed at 35 mg are the same patients who achieved a complete response at the lower does of 25 mg. ie. its says "Three patients were treated at 35 mg/m2 PTX-200 with no dose limiting toxicities reported. No additional clinical responses were seen in this cohort..... As previously reported, the three patients have achieved complete responses in the study so far."

I have underlined the because grammatically it links the two groups - grammatically it means that the 3 patients previously reported as having a complete response (at 25mg) are the same people who were enrolled for the higher dose level of 35mg.

But that seems odd to me. In their previous announcement of 20 August they did not say that the next cohort would be the same patients. Indeed - why continue to treat the same people, who have apparently been cured, when you could treat new patients and hopefully achieve the same result with them?

The other possibility is that they have a crap writer, and the word "the" should not have been included. If you delete it, then it would be reasonable to assume that the three patients at 35gm were new patients.

Don't get me wrong - this is still good news - but their communications are poor. For example, when did we last get an update on the PTX-200 studies in Breast cancer and Ovarian cancer? Both studies avchieved promising results but then, apart from a brief mention in the AGM presentation - silence. Or have I missed something?

I'm very hopeful for the future of PTX 100, PTX-200 and Omnicar. I just wish that PTX could communicate at least half as well as Imugene does.

Anyway - let's hope for more good results for all those people trying to beat AML. My heart goes out to them.

Cheers

Dave

Expand

Both Breast and Ovarian trials were promising. But, both have been put on hold. there was an announcemt some time ago about redesgning both trials and bringing them to Australia to help control costs. Cone of silence since then.
3 Upvote

0 Great analysis

Reply

Top Stories

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

There are more pages in this discussion • 21 more messages in this thread...

First 18 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 4.2¢		Change 0.001(2.44%)		Mkt cap ! $33.82M

Open	High	Low	Value	Volume
4.1¢	4.3¢	4.1¢	$27.29K	650.9K

Buyers (Bids)

No.	Vol.	Price($)
2	74314	4.1¢

Sellers (Offers)

Price($)	Vol.	No.
4.3¢	57451	1

View Market Depth

No.	Vol.	Price($)
1	20000	0.041
7	820840	0.040
6	547589	0.039
3	86160	0.038
4	470000	0.037

Price($)	Vol.	No.
0.043	57451	1
0.044	500000	1
0.045	868286	7
0.046	13200	1
0.047	525000	2

Last trade - 16.10pm 02/08/2024 (20 minute delay)

PTX (ASX) Chart

Ann: PTX-200 AML Trial Progresses to Higher Dose, page-18

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: PTX-200 AML Trial Progresses to Higher Dose, page-18

Top Stories

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News